Flublok 2026-2027 (influenza virus vaccine tv 2026-27(9 yrs and older)rcmb/PF)

No dosing information is available for this tab.

Seasonal influenza vaccine recombinant is administered only by IM injection. The vaccine should not be administered subcutaneously, intradermally, or IV.

Syncope (vasovagal or vasodepressor reaction; fainting) may occur following vaccination; such reactions occur most frequently in adolescents and young adults. Appropriate measures should be taken to decrease the risk of injury if a patient becomes weak or dizzy or loses consciousness (e.g., vaccinees should sit or lie down during and for 15 minutes after vaccination). If syncope occurs, the patient should be observed until symptoms resolve.

When multiple vaccines are administered during a single health-care visit, each parenteral vaccine should be given using separate syringes and different injection sites. Injection sites should be separated by at least 1 inch (if anatomically feasible) to allow appropriate attribution of any local adverse effects that may occur.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

Vaccines/Pariglasgene Brecaparvovec

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines. The mechanism is not known.(1)

CLINICAL EFFECTS: The expected serum antibody response may not be obtained.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The US manufacturer of pariglasgene brecaparvovec states that vaccines should be avoided for 1 month prior to pariglasgene brecaparvovec administration.(1)

DISCUSSION: Pariglasgene brecaparvovec therapy may decrease the effectiveness of vaccines.(1)

There are no severe interactions for this drug.

Moderate Interaction: Assess the risk to the patient and take action as needed.

Vaccines/Hepatitis B Vaccine (Fendrix)

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: No data is available on the concurrent administration of the hepatitis B vaccine Fendrix and other vaccines.(1)

CLINICAL EFFECTS: It is unknown if concurrent administration of the hepatitis B vaccine Fendrix and other vaccines will affect the efficacy of either vaccine.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: The Swedish manufacturer of Fendrix states that since there is no data available for the concurrent administration of Fendrix with other vaccines, the administration of Fendrix and other vaccines should be separated by 2 to 3 weeks.(1)

DISCUSSION: No data is available on the concurrent administration of the hepatitis B vaccine Fendrix with other vaccines.(1)

*History of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine.

There are no contraindication contraindications for this drug.

• Guillain-barre syndrome

There are no moderate contraindications for this drug.

In children 9 through 17 years of age, the most common (>=10%) solicited injection-site adverse reaction was pain (34.4%); the most common (>=10%) solicited systemic adverse reactions were myalgia (19.3%), headache (18.5%), and malaise (16.1%).

In adults 18 through 49 years of age, the most common (>=10%) injection-site adverse reaction was pain (37%); the most common (>=10%) solicited systemic adverse reactions were headache (15%), fatigue (15%), and muscle pain (11%).

In adults 50 through 64 years of age, the most common (>=10%) injection site adverse reaction was pain (32%); the most common (>=10%) solicited systemic adverse reactions were headache (17%), fatigue (13%), and muscle pain (11%).

In adults 65 years of age and older, the most common (>=10%) injection site adverse reaction was pain (19%); the most common (>=10%) solicited systemic adverse reactions were fatigue (13%) and headache (10%).

Rare or Very Rare

• Anaphylaxis
• Angioedema
• Bell's palsy
• Brachial plexus disorder
• Cellulitis
• Dyspnea
• Encephalopathy
• Guillain-barre syndrome
• Hypersensitivity drug reaction
• Myelitis
• Optic neuritis
• Serum sickness
• Stevens-johnson syndrome
• Thrombocytopenic disorder
• Vasculitis

More Frequent

• Bruising
• Chills
• Erythema
• Fatigue
• Headache disorder
• Induration of skin
• Injection site pain
• Injection site sequelae
• Malaise
• Myalgia
• Pruritus of skin

Less Frequent

• Appetite changes
• Arthralgia
• Cough
• Diarrhea
• Ecchymosis
• Fever
• Injection site erythema
• Injection site inflammation
• Nausea
• Pharyngitis
• Vomiting

Rare or Very Rare

• Back pain
• Dizziness
• Extensive limb swelling after injection
• Flushing
• Lymphadenopathy
• Neuralgia
• Pain in oropharynx
• Paresthesia
• Seizure disorder
• Skin rash
• Syncope
• Urticaria

No enhanced messaging available.

Safety and efficacy of influenza vaccine recombinant have not been established in individuals younger than 9 years of age.

Diminished hemagglutination inhibition (HI) antibody responses have been observed in children 6 months of age through 8 years of age who received either the trivalent or quadrivalent influenza vaccine recombinant, suggesting that the vaccine would not be effective in children younger than 9 years of age.

The manufacturer states that data are insufficient to assess the risk of using influenza vaccine recombinant in pregnant women.

The available data from a post-licensure, observational, retrospective, safety surveillance study in 14,981 pregnant individuals found no evidence of a vaccine-associated increase in the risk of major birth defects and miscarriages with the quadrivalent form of influenza vaccine recombinant; patients were exposed to the vaccine during the 28 days prior to conception or during pregnancy. The manufacturer states that data from the quadrivalent vaccine are relevant to the current trivalent formulation since both vaccines use the same manufacturing process and have overlapping compositions.

A pregnancy registry has been established to monitor fetal outcomes of pregnant women exposed to seasonal influenza vaccine recombinant; clinicians are encouraged to contact the registry at 800-822-2463 or online at https://www.sanofipasteurpregnancyregistry.com.

It is not known whether influenza vaccine recombinant is distributed into human milk. Data are insufficient to assess the effects on the breast-fed infant or on milk production.

The benefits of breast-feeding and the importance of the vaccine to the woman should be considered along with the potential adverse effects on the breast-fed child from the vaccine or from the underlying maternal condition (i.e., susceptibility to influenza infection).

ACIP states that recombinant vaccines do not pose any unusual risks for women who are breast-feeding or their breast-fed infants.

The manufacturer makes no special population dosage recommendations.

Clinical studies of influenza vaccine recombinant did not include sufficient numbers of patients 65 years of age and older to determine whether geriatric patients respond differently than younger adults.